drugset / Trial / NCT05060549

Dopamine D3 Receptor Occupancy in Bipolar Depression

NCT05060549

RandomizedParallel-groupOpen-labelBasic science

Summary

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Timeline

Start
2026-01-06
Primary completion
2027-05-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg
Subject Cariprazine Small molecule 3 mg

Indications